With generic versions of semaglutide being launched over the weekend at lower prices, the Indian drug regulatory authority has upped surveillance on the supply chain and unauthorised sale and promotion of the GLP-1 drugs, used to treat obesity and Type II diabetes.
“India’s Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use,” a note from the Union Health Ministry said.
With more options now in the market, “concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics,” the Ministry said, adding, “These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.”
In the recent weeks, enforcement activities have been scaled up, it said. “Audits and inspections were conducted at 49 entities, including: Online pharmacy warehouses, Drug wholesalers, Retailers, Wellness and slimming clinics.” The inspections were across the country and focused on “identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing. Further, notices have also been sent to defaulting entities,” it added.
Semaglutide is the active ingredient in Novo Nordik’s globally popular in weightloss and diabetes drugs Wegovy and Ozempic, respectively. A patent on semaglutide expired in markets including India last Friday, leading to over a handful of generic companies launching their less expensive versions of the drug in multiple delivery devices (vials with dose-specific syringes, pre-filled pens, injectables and tablets). The generic versions of the product are between 50 to 80 percent less than the innovator’s price.
Intensified surveillance
The regulatory surveillance will continue to be intensified in the coming weeks, the ministry said, and “non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws,” it added.
“The misuse of weight loss drugs without clinical oversight can lead to severe health complications,” the note reiterated, urging citizens to take treatment only on the prescription of qualified medical practitioners. The drug can be prescribed by endocrinologists, internal medicine specialists and for some indications by cardiologists, the note said.
More Like This
Published on March 24, 2026
Source link
#Indias #drug #regulatory #authority #steps #surveillance #generic #GLP1 #weightloss #drugs
